Back to results
US 2013/0096180 A1Published application
Bispecific Antisense Oligonucleotides that Inhibit IGFBP-2 and IGFBP-5 and Methods of Using Same
AssigneeThe University of British Columbia
InventorsMartin Gleave, Maxim Signaevsky
Life of this patent
Estimating the term…
Abstract
Bispecific antisense oligonucleotides which consist essentially of a sequence of bases that is complementary to portions of both the gene encoding human IGFBP-2 and the gene encoding human IGFBP-5 are useful in as antisense therapeutics in the treatment of endocrine-regulated cancers.
Claims9
1-18. (canceled)
A method of inhibiting expression of both human IGFBP-2 and human IGFBP-5 comprising exposing cells expressing human IGFBP-2 and human IGFBP-5 to a bispecific antisense oligonucleotide consisting of Seq ID No. 5, whereby expression of both human IGFBP-2 and human IGFBP-5 is inhibited.
Dependencies are inferred from the claim text.